Below you will find the latest press releases from Evolva. You are also welcome to dive into the archive and browse our press releases from there as well:
Latest Press Releases
Evolva and Cargill are pioneering the production of great tasting, next-generation sweeteners via fermentation
Reinach, Switzerland, 14 August 2014 – Evolva Holding SA (SIX: EVE) today announces it has entered into a contract (HDTRA1-14-C-0122) with the US Defense Threat Reduction Agency (DTRA)
Reinach, Switzerland, 4 August 2014 – Evolva Holding SA (SIX: EVE) today announces the acquisition of Cambridge, UK based Prosarix Ltd., a leading in silico (computational) modelling company.
Focus on Biosynthesis of High Value Indigenous Malaysian Natural Products
Reinach, Switzerland, 28 May 2014 – Evolva Holding SA (SIX: EVE) today announces the start of commercial production of its resveratrol ingredient.
Reinach, Switzerland, 23 May 2014 – The Annual General Meeting of Evolva Holding SA (SIX: EVE) has approved all proposals put forward by the Board of Directors.
Minneapolis and Reinach, Switzerland, 21 May 2014 – Cargill and Evolva Holding SA (SIX: EVE) today announced the achievement of a technical milestone in their joint development program of fermentation-based minor steviol glycosides - the compounds responsible for the sweet taste in the stevia leaf.
Reinach, Switzerland, 2 May 2014 – Evolva Holding SA (SIX: EVE) today announces the agenda for its Annual General Meeting of shareholders (AGM), to be held on 23 May 2014 in Basel, Switzerland. The full agenda is available on Evolva’s website under “investors/shareholder information”.
Reinach, Switzerland, 8 April 2014 – Evolva Holding SA (SIX: EVE) today announces its financial results for the period 1 January to 31 December 2013. The annual report is available on Evolva’s website.
Reinach, Switzerland, 5 March 2014 - Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) announces that Credit Suisse, who is acting as Sole Bookrunner in the private placement announced on 25 February 2014, has exercised in full the over-allotment option of 4,050,000 shares at the placement price of CHF 1.37 per share.
- 1 of 2
- next ›